| Compound | Area Under Investigation |
| Cardiovascular |
| AZD6370 | diabetes |
| Certriad | dyslipidaemia |
| AZD4017 | diabetes/obesity |
| AZD0837 | thrombosis |
| AZD6482 | thrombosis |
| Gastrointestinal |
| Lesogaberan (AZD3355) | GERD |
| AZD1386 | GERD |
| AZD2066 | GERD |
| AZD2516 | GERD |
| Infection |
| MEDI-560 | PIV prophylaxis |
| Motavizumab | RSV prevention |
| AZD7295 | Hepatitis C |
| Neuroscience |
| AZD6280 | anxiety |
| AZD8418 | schizophrenia |
| AZD8529 | schizophrenia |
| AZD7268 | depression/anxiety |
| AZD2327 | depression/anxiety |
| AZD2516 | chronic neuropathic pain |
| Seroquel XR | generalised anxiety disorder US |
| Oncology |
| MEDI-547 | solid tumours |
| AZD4769 | solid tumours |
| Faslodex | 1st line advanced breast cancer |
| Olaparib | gBRCA breast |
| Recentin | CRC |
| Recentin | recurrent glioblastoma |
| Respiratory & Inflammation |
| AZD9668 | COPD |
| AZD6553 | COPD |
| AZD2551 | COPD |
| AZD5122 | COPD |
| AZD5985 | asthma/COPD |
| AZD8075 | asthma/COPD |
| AZD8566 | COPD |
| AZD1236 | COPD |
| AZD9164 | COPD |
Comments
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed in this section has not been disclosed at this time.